Kaleido prices $75M IPO well below range; Sage raises $575M ahead of FDA decision
→ Kaleido Biosciences has raised $75 million to develop its microbiome metabolic therapies in a downsized IPO. The final going …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
